PaxMedica Logo
  • Home
  • About
  • FOCUS
    ASDFXTASHAT
  • Pipeline
  • Investors
  • News
  • Contact

Latest articles

All
News
Press Releases
Company Presentations
August 30, 2023
H.C. Wainwright 25th Annual Global Investment Conference

Live on Tuesday, 9/12 at 3:00 PM (Eastern Standard Time)

August 16, 2023
PXMD Business Update

Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD

July 24, 2023
Positive Top Line Results

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

July 6, 2023
PaxMedica Grants Exclusive Pharmacy Distribution Rights

Exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101, granted to Vox Nova LLC

June 20, 2023
The BRAIN Foundation Presents: Suramin for Autism

PaxMedica CEO Interviewed by The BRAIN Foundation

April 25, 2023
PaxMedica Rings the NASDAQ Closing Bell

PaxMedica Celebrates Autism Awareness Month

April 6, 2023
Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

March 30, 2023
Paxmedica Diving into the Investor Presentation with CEO Howard Weisman

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

March 20, 2023
PaxMedica Holds Meeting of Scientific Advisory Board

Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.

January 7, 2022
PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for...

July 19, 2021
PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program

David Hough, MD, CMO of PaxMedica will present trial results at the upcoming AACAP Annual Meeting during the “Research Pipeline: New Findings on Diagnostics and Therapeutics” program...

February 9, 2021
PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safety and tolerability profile

February 2, 2021
PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease

Company Pursuing Development of PAX-101 as Treatment for Autism Spectrum Disorder and Other Neurodevelopmental Conditions

Want to follow our progress?
Contact us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
HOMEABOUT
FOCUS
ASDFXTASHAT
PIPELINEINVESTORSNEWS
Linkedin Icon
© 2023 PaxMedica, Inc. All rights reserved.
303 S Broadway, Suite 125. Tarrytown, NY 10591
Legal Notice